06/04/2013 - 9:03am

At the 2013 Business and Leadership Conference in Orlando, Fla., HDMA honored pharmaceutical and consumer product manufacturers during the presentation of the 2013 Distribution Industry Awards for Notable Achievements in Healthcare.

06/03/2013 - 1:17pm

Another bill to limit dispensing of biosimilars lost Monday, this time in Illinois.

06/03/2013 - 10:18am

Dr. Reddy's Labs and Fujifilm have terminated a deal to market generic drugs in Japan, Dr. Reddy's said.

05/31/2013 - 5:14pm

There are several important pieces of legislation that will have an impact on the business of supermarket pharmacy if passed, noted Michael Spira, American Pharmacists Association senior lobbyist, during an FMI education session.

05/31/2013 - 5:07pm

Out of all retail pharmacy outlets, food stores have slightly increased their prescription sales, generating March year-to-date sales of $5.7 billion, up 0.5%, according to IMS Health data. Including drug, mail and independents, prescription sales totaled $58.3 billion, down 4.7%, reported Doug Long, VP industry relations for IMS Health, at an FMI education breakout.

05/31/2013 - 4:56pm

Antitrust attorney and pharmacy benefit management legal expert David Balto on Friday monitored a mini-summit helping supermarket pharmacy better navigate the PBM universe.

05/31/2013 - 1:42pm

India-based Sun Pharmaceutical Industries may buy Sweden-based Meda for $5 billion to $6 billion, according to published reports.

05/30/2013 - 9:42pm

While the passage of the Patient Protection and Affordable Care Act of 2010 was a milestone in a number of respects, it also was one of the biggest moments in the history of the generic drug industry since the 1984 passage of the Hatch-Waxman Act, which created an abbreviated regulatory approval pathway for generic pharmaceutical drugs.

05/30/2013 - 9:40pm

The year is only halfway done, but 2013 is already proving to be a year of particular importance for generic drugs as the industry awaits two important decisions from the Supreme Court and continues to wait for federal biosimilar regulations while fending off efforts to limit the scope of their use at the state level.